A coiled coil-based pre-targeting drug delivery system for precise treatment of breast cancer
Given the heterogeneous tumor environment and individual differences, separating the "targeting" and "killing" steps enables targeting molecules to bind to different antigens, followed by the application of the Zip1-drug complex without requiring antibody engineering. Our study highlights the potential of this pre-targeting system to efficiently deliver drugs, offering a promising strategy to address challenges faced by ADCs, such as poor tissue penetration, low accumulation, and "on-target, off-tumor" toxicity.
Authors
- Ivo Meihold-Heerlein
- T. M. Mohiuddin (ORCID: https://orcid.org/0000-0001-6022-1305)
- Marwah Al-Rawe
- Ahmad Fawzi Hussain (ORCID: https://orcid.org/0000-0002-1053-6939)
- Felix Alexander Zeppernick (ORCID: https://orcid.org/0000-0002-2909-9492)
- Chaoyu Zhang (ORCID: https://orcid.org/0000-0002-1123-4078)
- Roland Schmitz (ORCID: https://orcid.org/0000-0002-3348-6807)
- Marcus Niebert
- Wenjie Sheng
Institutions
- Justus-Liebig-Universität Gießen (DE)
Publication Details
- Journal
- European Journal of Pharmaceutics and Biopharmaceutics
- Published
- 2025-06-17
- DOI
- https://doi.org/10.1016/j.ejpb.2025.114794
- Citations
- 4
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 4.18